By combining AFP with other relevant biochemical markers, such as circulating tumor cells, tumor markers other than AFP (e.g., carcinoembryonic antigen, CA19-9), and specific gene expression profiles related to liver cancer, a more comprehensive and accurate predictive model can be developed. This evidence concerns the gene CEACAM5 and neoplasm.